From the monthly archives:

October 2009

The New York Times reported September 24, 2009 that the Food and Drug Administration (FDA) admitted “that four New Jersey congressmen and its own former commissioner unduly influenced the process that led to its decision last year to approve a patch for injured knees, an approval it is now revisiting.” [Blogger's note: all emphasized text throughout this post is mine.]

This admission by the FDA may shock some, but it will come as no surprise to lawyers for consumers who were killed or injured by dangerous drugs and medical devices approved by the FDA under the previous administration.  To lawyers engaged in the heated drug and medical-device litigation, it became obvious that some business men and women were willing to sit in their offices and boardrooms and take actions that would kill and permanently injure people.  The motive was greed, and the perpetrators were secure in their knowledge that, if the litigation went awry, the damages would be paid from the profits of the shareholders.  There was little or no personal responsibility for the decision-makers.  Sadly, some executives inside Big Pharma are still enjoying high compensation and fancy corporate perks after killing and injuring hundreds.  Contrast that with the day-to-day existence of someone serving prison time for killing or injuring just one person during a robbery, and it becomes clear why some became so outraged at the FDA under the previous administration.

The New York Times article goes on to report:

The agency’s scientific reviewers repeatedly and unanimously over many years decided that the device, known as Menaflex and manufactured by ReGen Biologics Inc., was unsafe because the device often failed, forcing patients to get another operation.

But after receiving what an F.D.A. report described as “extreme,” “unusual” and persistent pressure from four Democrats from New Jersey — Senators Robert Menendez and Frank R. Lautenberg and Representatives Frank Pallone Jr. and Steven R. Rothman — agency managers overruled the scientists and approved the device for sale in December.

All four legislators made their inquiries within a few months of receiving significant campaign contributions from ReGen, which is based in New Jersey, but all said they had acted appropriately and were not influenced by the money.

The New York Times later wrote an editorial about the corrupting effect of lobbying and political contributions on patient safety, concluding:

This shabby episode carries an important warning for policy makers as they debate health care reform. Decisions on what treatments work best have to be insulated from political lobbying. Otherwise there will be little hope for reining in spending on unproven treatments that may be ineffective or harmful.

Later the business press began to describe the story.  An Oct. 8, 2009 Wall Street Journal article discussed the effect of the FDA’s potentialy more stringent approval process on various medical-device manufacturers.  And, surprise, surprise, a securities analyst voiced the opinion that he is “‘very much concerned’ about tighter regulations that could slow the pace of innovation.” Even the pro-business Journal immediately followed that quote with this observation: “Device companies commonly rely on upgraded products cleared through 510(k) [the "fast-track approval process] that can fetch higher prices from hospitals.”

My thoughts after reading this disgusting saga:

  • Some people in a few big drug and medical-device companies really will kill you for your money, as some consumer attorneys have claimed for years.
  • Patients are safer under the current FDA Commissioner, but the bad guys are still out there, and they won’t quit trying simply because it’s gotten tougher.
  • Just because four congressmen from New Jersey wear the label “Democrat,” don’t expect them to protect consumers when business lobbyists are throwing money at them.  There are a few Republicans (Charles Grassley comes to mind) who seem to care more about patient safety and what’s going on at the FDA than the four guys from Jersey who ReGen’s money and pressured the FDA to approve an unsafe knee patch.  This isn’t a defense of Republicans; it’s more of an indictment of the current political and regulatory system, and my belief that a politician’s personal integrity and stand on the issues is more important than party labels.

{ 0 comments }

An Online Media Daily article reports that Google’s top-priced AdWord in 2008 was “mesothelioma” costing $99.44 per click. The article cites AdGooroo’s Search Engine Advertising Update: Q309. According to the same report, “mesothelioma” was also Yahoo’s top-priced word, at $60.68 per click. Rich Stokes, founder and CEO of AdGooroo, couldn’t say how many times the top keywords were clicked on each month.

{ 0 comments }

ConsumerNews.com: Still a work in progress.

by Michael J. Evans on October 9, 2009

in Consumer Protection

My favorite project right now is ConsumerNews.com, which I am developing as a news site after having spent decades representing plaintiffs. I firmly believe that huge corporations (who often find themselves as defendants in lawsuits) have funneled money into “think tanks” and the Chamber of Commerce to fund a decades-long attack on trial lawyers. I call this campaign “high-tech, high-priced jury tampering.” This unrelenting campaign has been so effective that people in some states have voted to give away their own Constitutional rights under the guise of “tort reform,” and some professional organizations have changed their names to get rid of the words “trial lawyers.” I still believe that it’s an honorable thing to represent individuals who have been injured or wronged by huge corporations.

That’s one of the reasons I’m interested in developing ConsumerNews.com. My vision for ConsumerNews is to build a reliable news site that will take an openly pro-consumer approach to reporting the news. Does this mean that the facts will be twisted to create pro-consumer news articles? Not at all. But it does mean that the articles will be factual, will be chosen to coincide with the concerns of individual consumers (including concerns that go beyond legal issues), and we will have no apologists standing ready to write an article justifying anything corporate America wishes to do. The plain, unvarnished truth is what is needed. As the masthead of the old Rocky Mountain News said: “Give light, and the people will find their own way.”

I’m learning that getting the bugs out of a substantial website can take longer than expected. In any event, we continue to make progress (though slower than we would like) and will announce the launch (when it comes) on this site.

{ 0 comments }

I’ve written before that attorneys who market over the Internet can gain a huge advantage from the use of well-optimized video.  As I mentioned in a post on the “Easiest way to a First Page Rank on Google“, Forrester Research has performed tests that show a video is 50 times more likely to be found on the first page of Google than a text page.

This has been consistently borne out in my own use of video in online legal marketing.  I’m involved in a project with other lawyers to represent victims of Yamaha Rhino rollovers.  We’ve posted two videos in connection with the project.  According to recent Wordtracker reports, the search term “Yamaha Rhino recall” is by far the most frequently searched term associated with Yamaha Rhinos.  I ran a Google search for “Yamaha Rhino recall” on October 7, 2009, and our two videos appeared in the top five results on Google’s first page.

Here’s a screenshot:

First page of a 10-7-09 Google search for "Yamaha Rhino recall"

First page of a 10-7-09 Google search for "Yamaha Rhino recall"

[click to continue…]

{ 0 comments }

The FTC finally got around to issuing guidelines for bloggers and “guerrilla marketers” who hype products in exchange for products or money.  If you have the time and interest, or if you need something to read before going to sleep, check out the 81-page- long Text of the Federal Register Notice.

Adweek notes: “The FTC chose not to make a distinction between professional bloggers and amateurs. It also does not differentiate between paying cash and providing product samples.  Violators face fines of up to $11,000 per infraction.”

{ 0 comments }